Clinical Manifestation and Management of Amyotrophic Lateral Sclerosis

  title={Clinical Manifestation and Management of Amyotrophic Lateral Sclerosis},
  author={Ashok K. Verma},
  journal={Amyotrophic Lateral Sclerosis},
  • A. Verma
  • Published 25 July 2021
  • Psychology, Medicine, Biology
  • Amyotrophic Lateral Sclerosis
ABSTRACT Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive neurodegenerative disease resulting in death in 2 to 4 years in most cases. There are several clinical subtypes of ALS depending on the degree of upper and lower motor neuron involvement, and recognition of these subtypes is important because certain subtypes have better prognosis. Without a reliable biomarker, ALS is a clinical diagnosis supported by laboratory investigations. The etiology of ALS remains unknown… 
Progress in Amyotrophic Lateral Sclerosis Gene Discovery
A consolidated update of the field can provide a launching point for researchers and clinicians to improve the search for ALS-related genes, defining pathogenic mechanisms, form diagnostics, and develop therapies.
Genetic Variability of Inflammation and Oxidative Stress Genes Affects Onset, Progression of the Disease and Survival of Patients with Amyotrophic Lateral Sclerosis
The data suggest that common genetic variants in the antioxidant and inflammatory pathways may modify ALS disease, and could support the identification of patients that may be responsive to the immune or antioxidant system—based therapies.


Amyotrophic lateral sclerosis
Two possible disease-modifying therapies that can slow disease progression are available for ALS, but patient management is largely mediated by symptomatic therapies, such as the use of muscle relaxants for spasticity and speech therapy for dysarthria.
The epidemiology of ALS: a conspiracy of genes, environment and time
The relationship between genetic and environmental risk factors is examined, and a disease model in which ALS is considered to be the result of environmental risks and time acting on a pre-existing genetic load is proposed, followed by an automatic, self-perpetuating decline to death.
Tale of two diseases: amyotrophic lateral sclerosis and frontotemporal dementia.
The recently reported ALS- FTD-linked genes and the emerging common unifying mechanism in the pathogenesis of ALS-FTD spectrum disorders are summarized along with a comment on the potential new therapeutic targets in these hitherto incurable diseases.
ALS Genetics, Mechanisms, and Therapeutics: Where Are We Now?
The genetic basis of ALS is reviewed, highlighting factors that have contributed to the elusiveness of genetic heritability and future directions for research that may lead to effective treatment strategies outlined.
Epidemiology of amyotrophic lateral sclerosis.
Motor neuron disease (MND) is used in this paper as the generic label, encompassing the clinical variants of amyotrophic lateral sclerosis, progressive myelopathic muscular atrophy, and progressive bulbar palsy, which indicates a male preponderance for ALS or MND as a whole.
Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000
Background: In recent years, there has been a paradigm shift in the method of healthcare delivery to amyotrophic lateral sclerosis (ALS) patients with the emergence of multidisciplinary ALS clinics
Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria
These revised consensus criteria expand upon those of 2009 and embrace the concept of the frontotemporal spectrum disorder of ALS (ALS-FTSD), which is a re-conceptualisation that neuropsychological deficits in ALS fall along a spectrum.
Corticospinal tract degeneration in the progressive muscular atrophy variant of ALS
A patient presenting with PMA with rapid clinical evolution likely has the pathology and pathophysiology of ALS whether or not upper motor neuron signs evolve.
A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group.
The antiglutamate agent riluzole appears to slow the progression of amyotrophic lateral sclerosis, and it may improve survival in patients with disease of bulbar onset, according to a prospective, double-blind, placebo-controlled trial in 155 outpatients with Amyotrophicateral sclerosis.